本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Elite Pharmaceuticals, Inc.

0.7111
-0.0189-2.59%
盤後0.71110.00000.00%16:00 EDT
成交量:192.12萬
成交額:137.85萬
市值:7.60億
市盈率:-56.64
高:0.7600
開:0.7600
低:0.6800
收:0.7300
資料載入中...

公司資料

公司名字:
Elite Pharmaceuticals, Inc.
交易所:
OTCQB
成立時間:
1997
員工人數:
64
公司地址:
165 Ludlow Avenue,Northvale,New Jersey,United States
郵編:
07647
電話:
傳真:
201 750 2755
簡介:
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company which is developing a pipeline of proprietary pharmacological abuse-deterrent opioid products as well as niche generic products. Elite specializes in oral sustained and controlled release drug products which have high barriers to entry. Elite owns generic products which have been licensed to TAGI Pharma, Epic Pharma, Dr. Reddy’s Laboratories, and Glenmark Pharmaceuticals, Inc., USA. Elite currently has eight commercial products being sold, six products filed with the FDA, additional approved products pending manufacturing site transfer and the NDA filing for SequestOx™. Elite’s pipeline products include abuse-deterrent opioids which utilize the Company’s patented proprietary technology and a once-daily opioid. These products include sustained release oral formulations of opioids for the treatment of chronic pain. These formulations are intended to address two major limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential opioid abuse. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ. Learn more at www.elitepharma.com.